iVascular has announced the release of Angiolite BTK, a sirolimus-eluting stent which has received CE mark approval for treating chronic and acute arterial lesions in lower limbs below the knee, improving blood flow in severe claudication and critical limb ischaemia.
The Angiolite BTK design has been specifically elaborated upon for drug-eluting stents and benefits from iVascular proprietary coating nanotechnology that yields a multilayer thin coating with optimal kinetics.
“Having the right bail-out options, when performing below-the-knee angioplasty, is extremely important in saving limbs,” claims Peter Goverde, a vascular surgeon at ZNA Stuivenberg Hospital, Antwerp, Belgium. “The latest generation drug-eluting stent, like the dedicated Angiolite BTK, can give you a solution and improve the outcome of your treatment.”
The first results of the clinical study, led by Goverde, demonstrated a six-month primary patency rate of 90% and amelioration in wound healing and reduction of major amputation.
“With this new launch, iVascular is proud to offer a complete portfolio for the treatment of endovascular pathologies,” said Lluis Duocastella, chief executive officer of iVascular.
